Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Phathom Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FIRST PATIENT DOSED, WITH TOPLINE RESULTS EXPECTED IN 2027 PHALCON-EOE-201 IS THE FIRST LARGE, WELL-CONTROLLED CLINICAL TRIAL OF AN ACID SECRETORY TREATMENT IN EOE FLORHAM PARK, N.J., NOV. 04, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY ANNOUNCED THE FIRST PATIENT HAS BEEN DOSED IN ITS PHASE 2 PHALCON-EOE-201 CLINICAL TRIAL EVALUATING VOQUEZNA (VONOPRAZAN) TABLETS AS AN INVESTIGATIONAL TREATMENT FOR EOSINOPHILIC ESOPHAGITIS (EOE) IN ADULTS.

PHATHOM PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 STUDY OF VOQUEZNA (VONOPRAZAN) IN EOSINOPHILIC ESOPHAGITIS (EOE)

FLORHAM PARK, N.J., NOV. 03, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, ANNOUNCED TODAY THAT MEMBERS OF ITS MANAGEMENT TEAM ARE SCHEDULED TO PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: GUGGENHEIM SECURITIES 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE IN BOSTON, MA DATE: MONDAY, NOVEMBER 10, 2025LIVE WEBCAST: 3:00 PM EST MANAGEMENT TO PARTICIPATE IN ONE-ON-ONE MEETINGS THROUGHOUT THE CONFERENCE STIFEL 2025 HEALTHCARE CONFERENCE IN NEW YORK, NY DATE: WEDNESDAY, NOVEMBER 12, 2025LIVE WEBCAST: 4:40 PM EST MANAGEMENT TO PARTICIPATE IN ONE-ON-ONE MEETINGS THROUGHOUT THE CONFERENCE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON, UK DATE: TUESDAY, NOVEMBER 18, 2025LIVE WEBCAST: 9:30 AM EST / 2:30 PM GMT MANAGEMENT TO PARTICIPATE IN ONE-ON-ONE MEETINGS THROUGHOUT THE CONFERENCE 16TH ANNUAL CRAIG-HALLUM ALPHA SELECT CONFERENCE IN NEW YORK, NY DATE: TUESDAY, NOVEMBER 18, 2025 MANAGEMENT TO PARTICIPATE IN ONE-ON-ONE MEETINGS THROUGHOUT THE CONFERENCE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE IN MIAMI, FL DATE: TUESDAY, DECEMBER 2, 2025LIVE WEBCAST: 3:25 PM EST MANAGEMENT TO PARTICIPATE IN ONE-ON-ONE MEETINGS THROUGHOUT THE CONFERENCE TO ACCESS THE LIVE WEBCAST AND ARCHIVED RECORDINGS OF EACH EVENT, VISIT THE NEWS & EVENTS SECTION OF THE PHATHOM WEBSITE AT HTTPS://INVESTORS.PHATHOMPHARMA.COM/NEWS-EVENTS/EVENTS-AND-PRESENTATIONS.

PHATHOM PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

OVER 790,000 TOTAL VOQUEZNA PRESCRIPTIONS FILLED TO DATE FILLED VOQUEZNA PRESCRIPTIONS INCREASED 28% FROM Q2 2025 NET REVENUES OF $49.5 MILLION, UP 25% QUARTER OVER QUARTER, AND CASH OPERATING EXPENSES DOWN 43% QUARTER OVER QUARTER FULL-YEAR 2025 REVENUE GUIDANCE UPDATED TO $170$175 MILLION; COMPANY EXPECTS TO ACHIEVE OPERATING PROFITABILITY IN 2026 MANAGEMENT TO HOST CONFERENCE CALL TODAY, OCTOBER 30, 2025, AT 8:00 A.M. ET FLORHAM PARK, N.J.

PHATHOM PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

FLORHAM PARK, N.J., OCT. 25, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY ANNOUNCED THAT RESULTS OF ADDITIONAL ANALYSES FROM ITS PIVOTAL PHASE 3 PHALCON-NERD-301 TRIAL EVALUATING VOQUEZNA (VONOPRAZAN) TABLETS IN PATIENTS WITH NON-EROSIVE REFLUX DISEASE (NERD) HAVE BEEN PUBLISHED IN THE AMERICAN JOURNAL OF GASTROENTEROLOGY. THE ARTICLE, TITLED VONOPRAZAN IMPROVES NOCTURNAL GASTROESOPHAGEAL REFLUX SYMPTOMS IN NON-EROSIVE REFLUX DISEASE, UNDERSCORES THE SIGNIFICANT BURDEN OF NIGHTTIME GERD SYMPTOMS AND THE POTENTIAL ROLE OF VOQUEZNA IN ADDRESSING THIS ASPECT OF THE DISEASE.

PHATHOM PHARMACEUTICALS ANNOUNCES PUBLICATION OF DATA FROM PHASE 3 PHALCON-NERD-301 STUDY SHOWING VOQUEZNA (VONOPRAZAN) IMPROVED NOCTURNAL GERD SYMPTOMS IN PATIENTS WITH NON-EROSIVE REFLUX DISEASE

FLORHAM PARK, N.J., OCT. 23, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY ANNOUNCED ITS PARTICIPATION IN THE AMERICAN COLLEGE OF GASTROENTEROLOGY'S (ACG) 2025 ANNUAL SCIENTIFIC MEETING, BEING HELD OCTOBER 24-29 IN PHOENIX, ARIZONA.

PHATHOM PHARMACEUTICALS TO HIGHLIGHT VOQUEZNA (VONOPRAZAN) AT THE AMERICAN COLLEGE OF GASTROENTEROLOGY (ACG) 2025 ANNUAL SCIENTIFIC MEETING

FLORHAM PARK, N.J., OCT. 20, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A LIVE WEBCAST AT 8:00 AM EDT ON THURSDAY, OCTOBER 30, 2025, TO REPORT ITS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE.

PHATHOM PHARMACEUTICALS TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON THURSDAY, OCTOBER 30, 2025

SANJEEV NARULA BRINGS PROVEN SUCCESS IN SCALING COMMERCIAL-STAGE BIOPHARMA COMPANIES WITH EXPERTISE IN CAPITAL AND INVESTOR STRATEGIES, M&A, AND OPERATIONAL EXCELLENCE APPOINTMENT STRENGTHENS PHATHOM'S LEADERSHIP TEAM AND ABILITY TO EXECUTE ITS GROWTH STRATEGY IN GI FLORHAM PARK, N.J., OCT. 06, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF SANJEEV NARULA AS CHIEF FINANCIAL AND BUSINESS OFFICER.

PHATHOM PHARMACEUTICALS APPOINTS SANJEEV NARULA AS CHIEF FINANCIAL AND BUSINESS OFFICER

FLORHAM PARK, N.J., AUG. 25, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, ANNOUNCED TODAY THAT MEMBERS OF ITS MANAGEMENT TEAM ARE SCHEDULED TO PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES IN SEPTEMBER:

FLORHAM PARK, N.J., AUG. 20, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), TODAY CLARIFIED THAT A SCHEDULE 13D FILING BY FRAZIER LIFE SCIENCES, WHICH IS EXPECTED TO BE FILED LATER TODAY, AUGUST 20, WILL INCLUDE ADMINISTRATIVE CHANGES TO ITS REPORTING APPROACH BUT DOES NOT REPRESENT A REDUCTION IN THE OWNERSHIP POSITION OF ANY FRAZIER FUND OR PERSON IN PHATHOM.

PHATHOM PHARMACEUTICALS CLARIFIES THAT THERE IS NO REDUCTION IN LEAD SHAREHOLDER'S OWNERSHIP FOLLOWING ADMINISTRATIVE CHANGE TO 13D FILING

FLORHAM PARK, N.J., AUG. 07, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED BUSINESS UPDATES.

PHATHOM PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

FLORHAM PARK, N.J., JULY 28, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A LIVE WEBCAST AT 8:00 AM EDT ON THURSDAY, AUGUST 7, 2025, TO REPORT ITS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE.

PHATHOM PHARMACEUTICALS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON THURSDAY, AUGUST 7, 2025

FLORHAM PARK, N.J., JUNE 23, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY ANNOUNCED THAT, IN CONNECTION WITH THE APPOINTMENT OF ANNE MARIE COOK AS CHIEF LEGAL OFFICER AND CORPORATE SECRETARY, THE COMPANY'S BOARD OF DIRECTORS HAS APPROVED THE GRANT OF INDUCEMENT AWARDS.

Phathom Pharmaceuticals, Inc.

PHAT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Phathom Pharmaceuticals, Inc.

PHAT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PHAT